131P - Breast-specific gamma imaging (BSGI) as follow-up after breast cancer surgery: Comparison with ultrasound and mammography

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Metastatic
Staging Procedures (clinical staging)
Surgical Oncology
Presenter Seong Yoon Yi
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors S.Y. Yi1, J.Y. Park2
  • 1Hematology-oncology, Inje University Ilsan Paik Hospital, 10380 - Goyang/KR
  • 2Radiology, Myongji Hospital, 412-270 - Goyang/KR



To evaluate breast-specific gamma imaging (BSGI) for detection of locoregional recurrence after surgery in breast cancer patients and to compare it with ultrasound and mammography.


Our study included 165 breast cancer patients who had undergone post-operative BSGI between August 2010 and December 2013. The imaging findings (BSGI, ultrasound [US] and mammography) were retrospectively reviewed for recurrence. The standard reference was the pathologic result and follow-up BSGI or US conducted within the past two years. The sensitivities, specificities, accuracies, negative predictive values (NPV), and positive predictive values (PPV) of BSGI, US and mammography were calculated.


Locoregional recurrence was confirmed in five patients. The recurrence sites were the contralateral breast (n = 1), ipsilateral breast (n = 1), ipsilateral axilla (n = 1), supraclavicular area (n = 1), and infraclavicular area (n = 1). The previous pathologic stagings were stage 1 (n = 1), 2 (n = 1), and 3 (n = 3). The sensitivities, specificities, PPV and NPV for recurrence were as follows: on BSGI, 40%, 88.1%, 9.5% and 97.9%; on US, 100%, 92.5%, 29.4% and 100%, and on mammography, 33.3%, 100%, 100% and 98.6%, respectively. The diagnostic accuracies of BSGI, US and mammography were 86.7%, 92.8%, and 98.6%.


The diagnostic accuracy of BSGI for detection of locoregional recurrence in breast cancer patients was 86.7%. BSGI was not superior to US or mammography in this regard. Therefore, BSGI should not be recommended for routine post-operative follow-up on breast cancer patients.

Clinical trial indentification

Legal entity responsible for the study

Inje University




All authors have declared no conflicts of interest.